Home › Facility Concerns Kill Lilly-Boehringer Diabetes Drug
 

Keywords :   


Facility Concerns Kill Lilly-Boehringer Diabetes Drug

2014-03-05 22:15:21| Agriculture - Topix.net

Eli Lilly and Boehringer-Ingelheim said that the Food and Drug Administration didn't approve their diabetes treatment empagliflozin because of concerns about a facility where the drug will be made.

Tags: drug concerns facility kill

Category:Agriculture and Forestry

Latest from this category

All news
27.11Washington Corner | November 2024
27.11Terminal crossbreeding: A missed opportunity
27.11Feedlot Forum 2025 features Cattle feeding in a changing environment
27.11Smithfield Foods continues support for Mayflower Marathon Holiday Food Drive
27.11Researchers turn to AI to optimize hog selling
27.11H5N1 in pigs: Where are the knowledge gaps?
26.11New swine respiratory disease treatment flexibility from nursery to finish
26.11Panel talks capturing added value in cattle
Agriculture and Forestry »
27.11 (uF6-060903
27.11 CD
27.11 155cm SALOMON 2461
27.11CISA &1227
27.11 110
27.11Lisa Larson 15271
27.1110REBORN
27.11CD glitsmotel urge blue
More »